
Sign up to save your podcasts
Or


CEO Christer Ahlberg describes the shortcomings of today's medicines, and why he believes a P-CAB is the answer. This therapy originated at AstraZeneca, though Cinclus owns it outright today, and is in a phase 3 that just started.
By BiotechTV5
44 ratings
CEO Christer Ahlberg describes the shortcomings of today's medicines, and why he believes a P-CAB is the answer. This therapy originated at AstraZeneca, though Cinclus owns it outright today, and is in a phase 3 that just started.

30,626 Listeners

1,863 Listeners

1,085 Listeners

325 Listeners

6,059 Listeners

60 Listeners

9,840 Listeners

86 Listeners

34 Listeners

19 Listeners

260 Listeners

497 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners